TPM003 (3-30 nmol/kg; subcutaneous injection; single dose) resulted in a dose-dependent and sustained decrease in body weight, food intake, and postprandial blood glucose in lean male C57BL/6J mice [1]. TPM003 (10 nmol/kg; subcutaneous injection; single dose) resulted in a sustained and significant decrease in body weight in obese male C57BL/6J mice induced by a high-fat diet [1]. TPM003 (10 nmol/kg; subcutaneous injection; once every 3 days for 21 days) resulted in a 30% reduction in body weight in obese male C57BL/6J mice induced by a high-fat diet, significantly inhibited food intake, and enhanced hepatic lipid clearance [1]. TPM003 (10 nmol/kg; subcutaneous injection; once daily or once every 3 days for 8 weeks) resulted in a significant reduction in body weight in mice induced by a high-fat diet and carbon tetrachloride (CCl4) and had an anti-fibrotic effect [1]. TPM003 (1.0-3.0 mg/kg; subcutaneous injection; twice a week for 4 weeks) caused a reversible and transient decrease in food intake and body weight in male and female SD rats without serious adverse reactions [1].

Animal/Disease Models:C57BL/6J (male, 8-10 weeks old) [1]
Doses: 3 nmol/kg; 10 nmol/kg; 30 nmol/kg
Route of Administration: Subcutaneous injection; Single dose
Experimental Results: The induced weight loss, cumulative food intake, and postprandial blood glucose levels decreased in a dose-dependent manner, reaching their maximum effect within 96 hours after administration. At a dose of 30 nmol/kg, the weight loss effect lasted until day 4, after which all indicators returned to baseline levels.

---

Animal/Disease Models:C57BL/6J (male, high-fat diet-induced obesity) [1]
Doses: 10 nmol/kg
Route of Administration: Subcutaneous injection; single dose
Experimental Results: Within 1-3 days after injection, body weight, cumulative food intake and blood glucose levels were significantly reduced. Compared with retatretide, it had better maximum weight loss and longer-lasting effects with no early rebound (unlike tezepatide, which rebounded on day 4).

---

Animal/Disease Models:C57BL/6J (male, high-fat diet-induced obesity) [1]
Doses: 10 nmol/kg
Route of Administration: Subcutaneous injection; every 3 days; for 21 days
Experimental Results: During the 21-day treatment period, body weight decreased by approximately 30%, and cumulative food intake was lower than that of mice treated with tezapeptide. Fasting blood glucose, plasma insulin, plasma alanine aminotransferase (ALT), serum triglycerides (TG), serum total cholesterol (TC), liver TG, and liver TC were all reduced to levels close to those of the lean mouse control group. Oil Red O staining showed that this study exhibited the most significant liver lipid droplet clearance rate compared to retatreptide and tezapeptide.

---

Animal/Disease Models:C57BL/6J (male, high-fat diet + carbon tetrachloride-induced non-alcoholic steatohepatitis) [1]
Doses: 10 nmol/kg
Route of Administration: Subcutaneous injection; once daily; for 8 weeks
Experimental Results: Compared with tezopastide, this product significantly reduced body weight, reduced liver weight to near the level of the lean control group, and significantly reduced liver collagen deposition by Masson's trichrome staining. This product significantly reduced the expression of key fibrosis markers: α-smooth muscle actin (α-SMA), fibronectin, and type I collagen α-1 chain (COL1A1), with the reduction in α-SMA expression being significantly greater than that of tezopastide.

---

Animal/Disease Models:C57BL/6J (male, Gubra Amylin NASH diet-induced NASH) [1]
Doses: 10 nmol/kg
Route of Administration: Subcutaneous injection; every 3 days; for 8 weeks
Experimental Results: Induced sustained progressive weight loss over 8 weeks (unlike retatrutide, which showed a partial rebound after week 3). Significantly reduced NAFLD activity score (NAS) compared to retatrutide and tirzepatide, particularly in terms of steatosis and hepatocyte ballooning degeneration. Reduced hepatic collagen deposition, COL1A1 and α-SMA expression, indicating a significant inhibitory effect on liver fibrosis and inflammation.

---

Animal/Disease Models:Sprague-Dawley mice (male and female, 8-10 weeks old)[1]
Doses: 1.0 mg/kg; 3.0 mg/kg
Route of Administration: Subcutaneous injection; twice a week; for 4 weeks
Experimental Results: Caused a transient decrease in food intake and body weight, and some animals occasionally experienced vomiting and mild diarrhea; all symptoms were reversible after discontinuation of the drug. No deaths, serious adverse events, significant serum biochemical pathological changes or histological abnormalities in key organs (thymus, spleen, mesenteric lymph nodes) were observed.

[1]. Discovery and Preclinical Evaluation of TPM003: A Novel GLP-1/GIP/Glucagon Triple Hormone Receptor Agonist with Robust Efficacy in Obesity and NASH. J Med Chem. 2026;69(4):4984-5001.

C238H370FN51O73S2

5196.91

Typically exists as solids at room temperature

O=C([C@@H](N)CC1=CC=C(C=C1)O)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](CC)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N2CCC[C@H]2C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N3CCC[C@H]3C(N4CCC[C@H]4C(N5CCC[C@H]5C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CSC6)=O)CC(C)C)=O)CC(C)C)=O)CC7=CC=C(O)C=C7)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CC8=CC=CC=C8)=O)CSCC(NCCN(C(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CCNC6=O)=O)=O)C)=O)CCC(N)=O)=O)C)=O)CCCCNC(C)=O)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)C)=O)[C@H](CC)C)=O)CO)=O)CC9=CC=C(O)C=C9)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC%10=C(C=CC=C%10)F)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)C

TG062

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)